The molecular pharmacology of estrogen receptor modulators: Implications for the treatment of breast cancer

Clinical Cancer Research

Volumn 11, Issue 2 II, 2005, Pages

  McDonnell, Donald P ^a   Yee, Douglas ^b   Santen, Richard ^b   Osborne, Kent ^b   Brodie, Angela ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Box 3813 ^*

Author keywords

[No Author keywords available]

Indexed keywords

4 (1,2 DIPHENYL 1 BUTENYL)CINNAMIC ACID; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT; HISTONE DEACETYLASE; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; UNCLASSIFIED DRUG; ZK 703;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER HORMONE THERAPY; CONFERENCE PAPER; DRUG CHOICE; DRUG RESISTANCE; HORMONE RECEPTOR INTERACTION; HUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; PROTEIN-TYROSINE KINASES; RECEPTORS, ESTROGEN;

EID: 12144262323     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (47)

1. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.
2. Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001;93:684-90.
3. Brodie A. Aromatase inhibitors in breast cancer. Trends Endocrinol Metab 2002;13:61-5.
4. Kuiper GGJM, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson J-A. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A 1996;93:5925-30.
5. Hall JM, McDonnell DP. The estrogen receptor β-isoform (ERβ) of the human estrogen receptor modulates ERα transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 1999;140:5566-78.
6. Weihua Z, Saji S, Mäkinen S, et al. Estrogen receptor (ER) β, a modulator of ERα in the uterus. Proc Natl Acad Sci U S A 2000;97:5936-41.
7. Harris HA, Albert LM, Leathurby Y, et al. Evaluation of an estrogen receptor-β agonist in animal models of human disease. Endocrinology 2003;144:4241-9.
8. Stein B, Yang MX. Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-κB and C/EBPβ. Mol Cell Biol 1995;15:4971-9.
9. Vegeto E, Belcredito S, Etteri S, et al. Estrogen receptor-α mediates the brain antiinflammatory activity of estradiol. Proc Natl Acad Sci U S A 2003;100:9614-9.
10. Jilka RL, Hangoc G, Girasole G, et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science 1992;257:88-91.
11. Edwards DP, Boonyaratanakornkit V. Rapid extranuclear signaling by the estrogen receptor (ER): MNAR couples ER and Src to the MAP kinase signaling pathway. Mol Interv 2003;3:12-5.
12. Improta-Brears T, Whorton AR, Codazzi F, York JD, Meyer T. Estrogen-induced activation of mitogen-activated protein kinase requires mobilization of intracellular calcium. Proc Natl Acad Sci U S A 1999;96:4686-91.
13. Chambliss KL, Yuhanna IS, Anderson RGW, Mendelsohn ME, Shaul PW. ERβ has nongenomic action in caveolae. Mol Endocrinol 2002;16:938-46.
14. McDonnell DP. The molecular pharmacology of SERMs. Trends Endocrinol Metab 1999;10:301-11.
15. Gottardis MM, Robinson SP, Jordan VC. Estradiol-stimulated growth of MCF-7 tumors implanted in athymic nude mice: a model to study the tumoristatic action of tamoxifen. J Steroid Biochem Mol Biol 1988;30:311-4.
16. Harper MJK, Walpole AL. A new derivative of triphenylethylene: effect on implantation and mode of action in rats. J Reprod Fertil 1967;13:101-19.
17. Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326:852-6.
18. McKenna NJ, Lanz RB, O'Malley BW. Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 1999;20:321-44.
19. Paige LA, Christensen DJ, Grøn H, et al. Estrogen receptor (ER) modulators each induce distinct conformational changes in ERα and ERβ. Proc Natl Acad Sci U S A 1999;96:3999-4004.
20. Wijayaratne AL, Nagel SC, Paige LA, et al. Comparative analyses of the mechanistic differences among antiestrogens. Endocrinology 1999;140:5828-40.
21. Norris JD, Paige LA, Christensen DJ, et al. Peptide antagonists of the human estrogen receptor. Science 1999;285:744-6.
22. Beekman JM, Allan GF, Tsai SY, Tsai M-J, O'Malley BW. Transcriptional activation by the estrogen receptor requires a conformational change in the ligand binding domain. Mol Endocrinol 1993;7:1266-74.
23. Pike ACW, Brzozowski AM, Hubbard RE, et al. Structure of the ligand-binding domain of oestrogen receptor β in the presence of a partial agonist and a full antagonist. EMBO J 1999;18:4608-18.
24. Pike ACW, Brzozowski AM, Walton J, et al. Structural insights into the mode of action of a pure antiestrogen. Structure 2001;9:145-53.
25. Shiau AK, Barstad D, Loria PM, et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998;95:927-37.
26. Smith CL, Conneely OM, O'Malley BW. Modulation of the ligand-independent activation of the human estrogen receptor by hormone and antihormone. Proc Natl Acad Sci U S A 1993;90:6120-4.
27. Ignar-Trowbridge DM, Pimentel M, Parker MG, McLachlan JA, Korach KS. Peptide growth factor cross-talk with the estrogen receptor requires the A/B domain and occurs independently of protein kinase C or estradiol. Endocrinology 1996;137:1735-44.
28. Osborne CK, Bardou V, Hopp TA, et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003;95:353-61.
29. Horwitz KB. When tamoxifen turns bad. Endocrinology 1995;136:821-3.
30. McDonnell DP, Clemm DL, Hermann T, Goldman ME, Pike JW. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol 1995;9:659-68.
31. Smith CL, O'Malley BW. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 2004;25:45-71.
32. Wijayaratne AL, McDonnell DP. The human estrogen receptor-α is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists and selective estrogen receptor modulators. J Biol Chem 2001;276:35684-92.
33. Allan GF, Leng X, Tsai SY, et al. Hormone and antihormone induce distinct conformational changes which are central to steroid receptor activation. J Biol Chem 1992;267:19513-20.
34. Howell A, DeFriend D, Robertson J, Blamey R, Walton P. Response to a specific antiestrogen (ICI182,780) in tamoxifen-resistant breast cancer. Lancet 1995;345:29-30.
35. Smith CL, Nawaz Z, O'Malley BW. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol 1997;11:657-66.
36. Anzick SL, Kononen J, Walker RL, et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 1997;277:965-8.
37. Howell SJ, Johnston SRD, Howell A. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer. Best Pract Res Clin Endocrinol Metab 2004;18:47-66.
38. Shang Y, Brown M. Molecular determinants for the tissue specificity of SERMs. Science 2002;295:2465-8.
39. Ariazi EA, Clark GM, Mertz JE. Estrogen-related receptor α and estrogen-related receptor γ associate with unfavorable and favorable biomarkers, respectively, in human breast cancer. Cancer Res 2002;62:6510-8.
40. Suzuki T, Miki Y, Moriya T, et al. Estrogen-related receptor α in human breast carcinoma as a potent prognostic factor. Cancer Res 2004;64:4670-6.
41. Jiang WG, Douglas-Jones A, Mansel RE. Expression of peroxisome- proliferator activated receptor-gamma (PPARγ) and the PPARγ co-activator, PGC-1, in human breast cancer correlates with clinical outcomes. Int J Cancer 2003;106:752-7.
42. Connor CE, Norris JD, Broadwater G, et al. Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor. Cancer Res 2001;61:2917-22.
43. Willson TM, Henke BR, Momtahen TM, et al. 3-[4-(1,2-diphenylbut-1-enyl) phenyl]acrylic acid: a non-steroidal estrogen with functional selectivity for bone over uterus in rats. J Med Chem 1994;37:1550-2.
44. Willson TM, Norris JD, Wagner BL, et al. Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of ER in bone. Endocrinology 1997;138:3901-11.
45. Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res 1991;51:3867-73.
46. Masamura S, Santner SJ, Heitjan DF, Santen RJ. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab 1995;80:2918-25.
47. Yue W, Wang J-P, Conaway M, Masamura S, Li Y, Santen RJ. Activation of the MAPK pathway enhances sensitivity of MCF-7 breast cancer cells to the mitogenic effect of estradiol. Endocrinology 2002;143:3221-9.